Abstract
Chromosome 17p deletions are associated with short survival and poor response to current chemotherapy treatment in non-Hodgkin's lymphomas. Although the prevailing view is that these deletions serve as a “second hit” event to inactivate p53, these deletions often hundreds of other genes. Using an in vivo RNAi screening approach for tumor suppressor genes, we identified and validated two additional tumor suppressors adjacent to p53 suggesting these deletions may do more than merely inactivate p53. To test this hypothesis, we constructed a new mouse model conditionally targeting a broad region of 17p and are intending to investigate whether and how genes co-deleted with well-known tumor suppressor p53 affect lymphoma development and chemotherapy responses. These results will elucidate the aggressive nature of tumors harboring 17p deletions and create the first mouse model that can be used to test strategies to overcome its deleterious effects.
Citation Format: Yu Liu, Claudio Scuoppo, Scott Lowe. The impact of chromosome 17p loss on cancer. [abstract]. In: Proceedings of the Third AACR International Conference on Frontiers in Basic Cancer Research; Sep 18-22, 2013; National Harbor, MD. Philadelphia (PA): AACR; Cancer Res 2013;73(19 Suppl):Abstract nr B34.
- ©2013 American Association for Cancer Research.